Summary & Overview
HCPCS J0641: Levoleucovorin Injection, 0.5 mg
HCPCS Level II code J0641 identifies the injectable oncology-support agent levoleucovorin in a 0.5 mg billing unit. Levoleucovorin is used as a chemoprotective and rescue agent in certain chemotherapy regimens; accurate coding ensures appropriate drug recognition and billing across outpatient infusion settings. Nationally, precise HCPCS coding for levoleucovorin affects drug pricing transparency, claims adjudication, and reporting for oncology services.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical sites of service, plus benchmarking and payment guidance where available. The publication outlines how J0641 is used on service lines for parenteral drug administration, summarizes payer coverage patterns, and highlights relevant policy implications for billing and claim processing.
This summary is intended to inform billing managers, practice administrators, and revenue-cycle professionals about the role of HCPCS Level II code J0641, common claim settings, and the types of information payers consider when processing injectable oncology-support drugs.
Billing Code Overview
HCPCS Level II code J0641 represents the administration of levoleucovorin injection, with the billing unit defined as 0.5 mg. The code denotes the drug product levoleucovorin, not otherwise specified, intended to be administered parenterally.
Service Type: Drug administration (injectable therapeutic agent)
Typical Site of Service: Hospital outpatient department, physician office, or ambulatory infusion center, reflecting usual locations where injectable chemoprotective or supportive oncology agents are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving folinic acid rescue after high-dose methotrexate or to mitigate fluoropyrimidine toxicity. The medication J0641 (injection, levoleucovorin, 0.5 mg) is administered when intravenous or intramuscular levoleucovorin is indicated to reduce methotrexate-related cytotoxicity or to treat toxicity from fluorouracil overdose. Clinical workflow: the oncology clinician orders levoleucovorin with dose calculated by weight or protocol; pharmacy prepares the injectable vials or syringes; nursing verifies the order, performs medication reconciliation and allergy check, obtains informed consent when required, and administers the injection via IV push or IV infusion in the outpatient infusion center, hospital inpatient unit, or emergency department. Documentation includes indication, dose (and number of 0.5 mg units billed), route, site of service, start and stop times, lot and expiration for drug accountability, and any immediate adverse reactions. Typical monitoring includes vital signs, assessment for signs of allergic reaction, and laboratory review of methotrexate levels when used as rescue therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Use when part of the levoleucovorin supply is discarded and must be reported separately under payer policies for discarded drugs. |